Diverse glial cell line-derived neurotrophic factor (GDNF) support between mania and schizophrenia: A comparative study in four major psychiatric disorders

European Psychiatry

Volumn 30, Issue 2, 2015, Pages 198-204

  Tunca, Z ^a   Kivircik Akdede, B ^a   Ozerdem A ^a   Alkin, T ^a   Polat, S ^b   Ceylan, D ^b   Bayin, M ^b   Cengizcetin Kocuk N ^b   Simsek S ^b   Resmi, H ^a   Akan, P ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Brain derived neurotrophic factor (BDNF); Depression; Glial cell line derived neurotrophic factor (GDNF); Mania; Obsessive compulsive disorder; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CHLORPROMAZINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; MOOD STABILIZER; NEUROLEPTIC AGENT; GDNF PROTEIN, HUMAN;

ADULT; ARTICLE; BIPOLAR DEPRESSION; BIPOLAR DISORDER; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DSM-IV; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MANIA; MENTAL DISEASE; NERVE CELL PLASTICITY; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHIZOPHRENIA; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; BLOOD; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; MAJOR DEPRESSION; MIDDLE AGED; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX;

EID: 84921277872     PISSN: 09249338     EISSN: 17783585     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2014.11.003     Document Type: Article

References (81)

1. Airaksinen M.S., Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 2002, 3:383-394.
2. Allen N.J., Barres B. Signaling between glia and neurons: focus on synaptic plasticity. Curr Opin Neurobiol 2005, 5:542-548.
3. Angelucci F., Brenè S., Mathé A.A. BDNF in schizophrenia, depression and corresponding animal models. Mol Psychiatry 2005, 10:345-352.
4. Autry A.E., Monteggia L.M. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol Rev 2012, 64:238-258.
5. Bai O., Chlan-Fourney J., Bowen R., Keegan D., Li X.M. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J Neurosci Res 2003, 71:127-131.
6. Balaratnasingam S., Janca A. Brain-derived neurotrophic factor: a novel neurotrophin involved in psychiatric and neurological disorders. Pharmacol Ther 2012, 134:116-124.
7. Barbosa I.G., Huguet R.B., Sousa L.P., Abreu M.N.S., Rocha N.P., Bauer M.E., et al. Circulating levels of GDNF in bipolar disorder. Neurosci Lett 2011, 502:103-106.
8. Bezzi P., Volterra A. A neuron-glia signalling network in the active brain. Curr Opin Neurobiol 2001, 11:387-394.
9. Bocchio-Chiavetto L., Bagnardi V., Zanardini R., Molteni R., Nielsen M.G., Placentino A., et al. Serum and plasma BDNF levels in major depression: a replication study and meta-analyses. World J Biol Psychiatry 2010, 11:763-773.
10. Buckley P.F., Pillai A., Howell K.R. Brain-derived neurotrophic factor: findings in schizophrenia. Curr Opin Psychiatry 2011, 24:122-127.
11. Busner J., Targum S.D. The Clinical Global Impressions Scale applying a research tool in clinical practice. Psychiatry 2007, 4:28-37.
12. Cotter D.R., Pariante C.M., Everall I.P. Glial cell abnormalities in major psychiatric disorders: the evidence and implications. Brain Res Bull 2001, 55:585-595.
13. Diniz B.S., Teixeira A.L., Miranda A.S., Talib L.L., Gattaz W.F., Forlenza O.V. Circulating Glial-derived neurotrophic factor is reduced in late-life depression. J Psychiat Res 2012, 46:135-139.
14. dos Santos I.M., Ciulla L., Braga D., Ceresér K.M., Gama C.S., Kapczinski F., et al. Symptom dimensional approach and BDNF in unmedicated obsessive-compulsive patients: an exploratory study. CNS Spectr 2011, 16:179-189.
15. Duman R.S., Malberg J., Nakagawa S., D'Sa C. Neuronal plasticity and survival in mood disorders. Biol Psychiatry 2000, 48:732-739.
16. Durany N., Michel T., Zöchling R., Boissl K.W., Cruz-Sánchez F.F., Riederer P., et al. Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr Res 2001, 52:79-86.
17. Encinas M., Tansey MG, Tsui-Pierchala B.A., et al. c-Src is required for glial cell line-derived neurotrophic factor (GDNF) family ligand-mediated neuronal survival via a phosphatidylinositol-3 kinase (PI-3K)-dependent pathway. J Neurosci 2001, 21:1464-1472.
18. Favalli G., Li J., Belmonte-de-Abreu P., Wong A.H.C., Daskalakis Z.J. The role of BDNF in the pathophysiology and treatment of schizophrenia. J Psychiatr Res 2012, 46:1-11.
19. Fernandes B.S., Berk M., Turck C.W., Steiner J., Gonçalves C. Decreased peripheral brain-derived neurotrophic factor levels are a biomarker of disease activity in major psychiatric disorders: a comparative meta-analysis. Mol Psychiatry 2014, 19:750-751.
20. Fernandes B.S., Gama C.S., Ceresér K.M., Yatham L.N., Fries G.R., Colpo G., et al. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res 2011, 45:995-1004.
21. First M.B., Spitzer R.L., Gibbon M. Structured clinical interview for DSM-IV-TR Axis I Disorders, research version 2002, Biometrics Research, New York State Psychiatric Institute, New York.
22. Fontenelle L.F., Barbosa I.G., Victor Luna J., Pessoa Rocha N., Silva Miranda A., Teixeira A.L. Neurotrophic factors in obsessive-compulsive disorder. Psychiatry Res 2012, 199:195-200.
23. Frye M.A., Watzl J., Banakar S., O'Neill J., Mintz J., Davanzo P., et al. Increased anterior cingulate/medial prefrontal cortical glutamate and creatine in bipolar depression. Neuropsychopharmacology 2007, 32:2490-2499.
24. Gama C.S., Andreazza A.C., Kunz M., Berk M., Belmonte-de-Abreu P.S., Kapczinski F. Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder. Neurosci Lett 2007, 420:45-48.
25. Gardner D.M., Murphy A.L., O'Donnell H., Centorrino F., Baldessarini R.J. International consensus study of antipsychotic dosing. Am J Psychiatry 2010, 167:686-693.
26. González-Pinto A., Mosquera F., Palomino A., Alberich S., Gonza A., Ortiz A. Increase in brain-derived neurotrophic factor in first-episode psychotic patients after treatment with atypical antipsychotics. Int Clin Psychopharmacol 2010, 25:241-245.
27. Goodman W.K., Price L.H., Rasmussen S.A., Mazure C., Fleischmann R.L., Hill C.L., et al. The Yale-Brown Obsessive-compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 1989, 46:1006-1011.
28. Gould T.D., Zarate C.A., Manji H.K. Glycogen synthase kinase-3: a target for novel bipolar disorder treatments. J Clin Psychiatry 2004, 65:10-21.
29. Granholm C., Reyland M., Albeck D., Sanders L., Gerhardt G., Hoernig G., et al. Glial cell line-derived neurotrophic factor is essential for postnatal survival of midbrain dopamine neurons. J Neurosci 2000, 20:3182-3190.
30. Green M.J., Matheson S.L., Shepherd A., Weickert C.S., Carr V.J. Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis. Mol Psychiatry 2011, 16:960-972.
31. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960, 23:56-62.
32. Hansen R.A., Moore C.G., Dusetzina S.B., Leinwand B.I., Gartlehner G., Gaynes B.N. Controlling for drug dose in systematic review and meta-analysis: a case study of the effect of antidepressant dose. Med Decis Making 2009, 29:91-103.
33. Hisaoka K., Nishida A., Koda T., Miyata M., Zensho H., Morinobu S., et al. Antidepressant drug treatments induce glial cell line-derived neurotrophic factor (GDNF) synthesis and release in rat C6 glioblastoma cells. J Neurochem 2001, 79:25-34.
34. Hisaoka K., Takebayashi M., Tsuchioka M., Maeda N., Nakata Y. Antidepressants increase glial cell line-derived neurotrophic factor production through monoamine-independent activation of protein tyrosine kinase and extracellular signal-regulated kinase in glial cells. J Pharmacol Exp Ther 2007, 321:148-157.
35. Hunsberger J., Austin D.R., Henter I.D. The neurotrophic and neuroprotective effects of psychotropic agents. Dialogues Clin Neurosci 2009, 11:333-348.
36. Jindal R.D., Pillai A.K., Mahadik S.P., Eklund K., Montrose D.M., Keshavan M.S. Decreased BDNF in patients with antipsychotic naïve first-episode schizophrenia. Schizophr Res 2010, 119:47-51.
37. Karege F., Perret G., Bondolfi G., Schwald M., Bertschy G., Aubry J.M. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res 2002, 109:143-148.
38. Kay S.R., Fiszbein A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
39. Kondziella D., Brenner E., Eyjolfsson E.M., Sonnewald U. How do glial-neuronal interactions fit into current neurotransmitter hypotheses of schizophrenia?. Neurochem Int 2007, 50:291-301.
40. Lee K., Kunugi H., Nanko S. Glial cell line-derived neurotrophic factor (GDNF) gene and schizophrenia: polymorphism screening and association analysis. Psychiatry Res 2001, 104:11-17.
41. Lee B.H., Kim Y.K. Increased plasma brain-derived neurotropic factor, not nerve growth factor-Beta, in schizophrenia patients with better response to risperidone treatment. Neuropsychobiol 2009, 59:51-58.
42. Lin P.Y. State-dependent decrease in levels of brain-derived neurotrophic factor in bipolar disorder: a meta-analytic study. Neurosci Lett 2009, 466:139-143.
43. Lin L.F., Doherty D.H., Lile J.D., Bektesh S., Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993, 21:1130-1132.
44. Liu Q., Zhu H.Y., Li B., Wang Y.Q., Yu J., Wu G.C. Chronic clomipramine treatment restores hippocampal expression of glial cell line-derived neurotrophic factor in a rat model of depression. J Affect Disord 2012, 141:367-372.
45. Maina G., Rosso G., Zanardini R., Bogetto F., Gennarelli M., Bocchio-Chiavetto L. Serum levels of brain-derived neurotrophic factor in drug-naïve obsessive-compulsive patients: a case-control study. J Affect Disord 2010, 122:174-178.
46. 1H-MRS studies. Schizophr Bull 2013, 39:120-129.
47. Michel T.M., Frangou S., Camara S., Thiemeyer D., Jecel J., Tatschner T., et al. Altered glial cell line-derived neurotrophic factor (GDNF) concentrations in the brain of patients with depressive disorder: a comparative postmortem study. Eur Psychiatry 2008, 23:413-420.
48. Michelato A., Bonvicini C., Ventriglia M., Scassellati C., Randazzo R., Bignotti S., et al. 3' UTR(AGG)n repeat of glial cell line-derived neurotrophic factor (GDNF) gene polymorphism in schizophrenia. Neurosci Lett 2004, 357(3):235-237.
49. Mizuno T., Omata N., Murata T., Mitsuya H., Maruoka N., Mita K., et al. Mania: not the opposite of depression, but an extension? Neuronal plasticity and polarity. Med Hypotheses 2013, 81:175-179.
50. Niitsu T., Shirayama Y., Matsuzawa D., Shimizu E., Hashimoto K., Iyo M. Association between serum levels of glial cell line-derived neurotrophic factor and attention deficits in schizophrenia. Neurosci Lett 2014, 575:37-41.
51. Ohrmann P., Siegmund A., Suslow T., Spitzberg K., Kersting A., Arolt V., et al. Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study. Schizophr Res 2005, 73:153-157.
52. Olbrich H.M., Valerius G., Rüsch N., Buchert M., Thiel T., Hennig J., et al. Frontolimbic glutamate alterations in first-episode schizophrenia: evidence from a magnetic resonance spectroscopy study. World J Biol Psychiatry 2008, 9:59-63.
53. Ongur D., Drevets W.C., Price J.L. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci U S A 1998, 95:13290-13295.
54. Ongur D., Jensen J.E., Prescot A.P., Stork C., Lundy M., Cohen B.M., et al. Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania. Biol Psychiatry 1998, 90:13290-13295.
55. Otsuki K., Uchida S., Watanuki T., Wakabayashi Y., Fujimoto M., Matsubara T., et al. Altered expression of neurotrophic factors in patients with major depression. J Psychiatr Res 2008, 42:1145-1153.
56. Patil S.T., Zhang L., Martenyi F., Lowe S.L., Jackson K.A., et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 2007, 13:1102-1107.
57. Paz R.D., Tardito S., Atzori M., Tseng K.Y. Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology. Eur Neuropsychopharmacol 2008, 18:773-786.
58. Pirildar S., Gönül A.S., Taneli F., Akdeniz F. Low serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment. Prog Neuropsychopharmacol Biol Psychiatry 2004, 28:709-713.
59. Pittenger C., Krystal J.H., Coric V. Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx 2006, 3:69-81.
60. Rajkowska G. Dysfunction in neural circuits involved postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol Psychiatry 2000, 48:766-777.
61. Rizos E.N., Papathanasiou M., Michalopoulou P.G., Mazioti A., Douzenis A., Kastania A., et al. Association of serum BDNF levels with hippocampal volumes in first psychotic episode drug-naive schizophrenic patients. Schizophr Res 2011, 129:201-204.
62. Rorick-Kehn L.M., Johnson B.G., Knitowski K.M., Salhoff C.R., Witkin J.M., Perry K.W., et al. In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders. Psychopharmacology (Berl) 2007, 193:121-136.
63. Rosa A.R., Frey B.N., Andreazza A.C., Ceresér K.M., Cunha A.B.M., Quevedo J., et al. Increased serum glial cell line-derived neurotrophic factor immunocontent during manic and depressive episodes in individuals with bipolar disorder. Neurosci Lett 2006, 407:146-150.
64. Saavedra A., Baltazar G., Santos P., Carvalho C.M., Duarte E.P. Selective injury to dopaminergic neurons up-regulates GDNF in substantia nigra postnatal cell cultures: role of neuron-glia crosstalk. Neurobiol Dis 2006, 23:533-542.
65. Shao Z., Dyck L.E., Wang H., Li X.M. Antipsychotic drugs cause glial cell line-derived neurotrophic factor secretion from C6 glioma cells. J Psychiatry Neurosci 2006, 31:32-37.
66. Sharma H.S. Post-traumatic application of brain-derived neurotrophic factor and glia-derived neurotrophic factor on the rat spinal cord enhances neuroprotection and improves motor function. Acta Neurochir 2006, 96(Suppl.):329-334.
67. Takebayashi M., Hisaoka K., Nishida A., Tsuchioka M., Miyoshi I., Kozuru T., et al. Decreased levels of whole blood glial cell line-derived neurotrophic factor (GDNF) in remitted patients with mood disorders. Int J Neuropsychopharmacol 2005, 9:1-6.
68. Théberge J., Williamson K.E., Aoyama N., Drost D.J., Manchanda R., Malla A.K., et al. Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia. Br J Psychiatry 2007, 191:325-334.
69. Toyooka K., Asama K., Watanabe Y., Muratake T., Takahashi M., Someya T. Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Res 2002, 110:249-257.
70. Tunca Z., Ozerdem A., Ceylan D., Yalçin Y., Can G., Resmi H., et al. Alterations in BDNF (brain-derived neurotrophic factor) and GDNF (glial cell line-derived neurotrophic factor) serum levels in bipolar disorder: the role of lithium. J Affect Disord 2014, 166:193-200.
71. Young R.C., Biggs J.T., Ziegler V.E., Meyer D.A. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978, 133:429-435.
72. Yoshimura R., Hori H., Ikenouchi-sugita A., Umene-nakano W., Katsuki A. Aripiprazole altered plasma levels of brain-derived neurotrophic factor and catecholamine metabolites in first-episode untreated Japanese schizophrenia patients. Hum Psychopharmacol 2012, 27:33-38.
73. Wang Y., Mathews C.A., Li Y., Lin Z., Xiao Z. Brain-derived neurotrophic factor (BDNF) plasma levels in drug-naïve OCD patients are lower than those in healthy people, but are not lower than those in drug-treated OCD patients. J Affect Disord 2011, 133:305-310.
74. Weickert C.S., Hyde T.M., Lipska B.K., Herman M.M., Weinberger D.R., Kleinman J.E. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol Psychiatry 2003, 8:592-610.
75. Williams H.J., Norton N., Peirce T., Dwyer S., Williams N.M., Moskvina V., et al. Association analysis of the glial cell line-derived neurotrophic factor (GDNF) gene in schizophrenia. Schizophr Res 2007, 97:271-276.
76. Xiu M.H., Hui L., Dang Y.F., Hou T.D., Zhang C.X., Zheng Y.L. Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:1508-1512.
77. Vostrikov V.M., Uranova N.A., Orlovskaya D.D. Deficit of perineuronal oligodendrocytes in the prefrontal cortex in schizophrenia and mood disorders. Schizophr Res 2007, 94:273-280.
78. Zagrebelsky M., Korte M. Neuropharmacology form follows function: BDNF and its involvement in sculpting the function and structure of synapses. Neuropharmacol 2014, 76:628-638.
79. Zarate C., Du J., Quiroz J., Gray N., Denicoff K., Singh J., et al. Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system. Ann N Y Acad Sci 2003, 1003:273-291.
80. Zhang X., Zhang Z., Xie C., Xi G., Zhou H., Zhang Y., et al. Effect of treatment on serum glial cell line-derived neurotrophic factor in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:886-890.
81. Zurn D., Winkel L., Menoud A., Djabali K., Aebischer P. Combined effects of GDNF, BDNF, and CNTF on motoneuron differentiation in vitro. J Neurosci Res 1996, 44:133-141.